Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

(RTTNews) - Santhera Pharmaceuticals reported total revenue from contracts with customers of 39.1 million Swiss francs compared to 103.4 million francs, prior year. Product sales were 14.8 million ...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 - Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 and beyond. Dario Eklund, CEO of ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AMN Healthcare Services (AMN – Research ...

Santhera's Duchenne muscular dystrophy (DMD) therapy Agamree has been cleared for NHS use after a confidential pricing agreement. The deal means that Agamree (vamorolone) will be available to ...

Santhera has agreed pricing and reimbursement for its Duchenne muscular dystrophy drug Agamree with German health funds representing 90% of patients.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...